Disease/Infection News

RSS

Bloomberg Businessweek explores growing trend in pharma to license, donate HIV drugs

"Pharmaceutical companies, once blasted as uncaring or downright greedy for charging thousands of dollars for a year's worth of AIDS medicines … in poor countries, lately have been slashing prices and licensing their drugs for free or nominal cost to nonprofits or local manufacturers in the developing world," Bloomberg BusinessWeek writes in an analysis piece that examines how this trend, combined with a growing capability among aid agencies to distribute drugs, has the potential to increase access to HIV/AIDS drugs worldwide.

7 Aug 2010

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Two studies published online Thursday in the Lancet show that the rotavirus vaccine is safe and effective at preventing much of the gastrointestinal illness in developing countries, where rotavirus kills more than 400,000 children under age 5 annually, Reuters reports. Based on the findings in Asia and Africa, the studies' authors "urged the governments of developing nations to make the vaccines a priority," the news service writes.

7 Aug 2010

Boston Globe examines rise of polio in Tajikistan, other pockets of world

"Polio has reappeared in a corner of the world that had not seen cases in years - Tajikistan, the former Soviet republic - a chilling setback in the two-decade campaign to purge a dreaded cause of childhood paralysis from the planet," the Boston Globe reports in a story that examines the reemergence of polio in other areas of the world.

7 Aug 2010

Multiple tattoos increase risk of contracting hepatitis C: Study

Youth, prison inmates and individuals with multiple tattoos that cover large parts of their bodies are at higher risk of contracting hepatitis C and other blood-borne diseases, according to a University of British Columbia study.The researchers reviewed and analysed 124 studies from 30 countries, including Canada, Iran, Italy, Brazil and the United States, and found the incidence of hepatitis C after tattooing is directly linked with the number of tattoos an individual receives. The findings are published in the current issue of the International Journal of Infectious Diseases.

7 Aug 2010

Equatorial Guinea, ECCAS partner to form network to fight H1N1, HIV

Equatorial Guinea (Republica de Guinea Ecuatorial) and the Global Viral Forecasting Initiative, along with several Central African States, have partnered with the Economic Community of Central African States to form a network to fight H1N1 and HIV. The purpose of the network's recent forum was to share knowledge and best practices, and to collect data and prevention procedures among military health professionals in the region.

7 Aug 2010

Recent releases in Global Health

According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."

7 Aug 2010

Dermatologist discusses on common nail ailment prevention

For many people, the phrase "tough as nails" doesn't apply to their own nails. Instead of strong nails, their nails may be brittle and break or split easily. Or, nail fungus might cause nails to look unattractive and unhealthy. Fortunately, dermatologists can help people improve the health and overall appearance of their nails with proper diagnosis and treatment.

6 Aug 2010

Kaiser Family Foundation/CSIS forum reviews AIDS 2010, looks ahead to AIDS 2012

Last month's 18th International AIDS Conference-AIDS 2010 in Vienna, Austria, will be remembered as the first since the global economic downturn, the growing recognition of treatment as part of prevention and a focus on the importance of human rights, HIV/AIDS experts said Thursday during a panel discussion in Washington, D.C. A webcast of the event is available online.

6 Aug 2010

Risk of epidemic is high in Pakistan: Canadian Red Cross

The Red Cross Red Crescent Movement is ramping up its relief operations in response to flooding in Pakistan. Over three million people have been affected as the worst flooding in 80 years wreaks havoc across 70 per cent of the country. Despite a rapid humanitarian response Red Cross officials warn that the worst may be yet to come.

6 Aug 2010

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.

6 Aug 2010

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Vaccines have a long history of successfully preventing disease and, in effect, improving the lives of countless Americans. Now, two serious diseases - human papillomavirus (HPV) and herpes zoster - could become a thing of the past as people better understand the safety and efficacy of vaccines to prevent these serious viral infections in specific populations.

6 Aug 2010

Research on human disease origins to predict, prevent next outbreak

Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.

6 Aug 2010

SeraCare optimizes ACCURUN 341 Nucleic Acid Positive controls

SeraCare Life Sciences, Inc. today announced that the Company has developed a new series of controls in its ACCURUN portfolio to monitor and validate molecular diagnostic test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). Through collaboration with instrument and reagent manufacturers, SeraCare has optimized the ACCURUN 341 Nucleic Acid Positive controls specifically for use with the three most popular assays currently on the market; the Gen-Probe APTIMA Combo 2 Assay, the Roche COBAS AMPLICOR CT/NG Test, and the Becton, Dickinson BD ProbeTec ET System.

6 Aug 2010

Scientists to develop new antibiotics to tackle infection-causing bacteria

Detailed pictures published today reveal how a new type of experimental antibiotic can kill bacteria that are already resistant to existing treatments. The findings could ultimately help scientists to develop new antibiotics to tackle the bacteria responsible for many hospital and community-acquired infections.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Researchers map malaria parasite P vivax; Nearly 3B people at risk of infection in 2009

A new evidence-based map estimates that in 2009 2.85 billion people lived "at risk of infection" with the malaria parasite Plasmodium vivax, BMJ News reports. As described in a study, published Tuesday in PLoS Neglected Tropical Diseases, P vivax "is more widespread and potentially represents a greater burden on human health in some parts of the world than P falciparum, the species usually associated with the greatest mortality and morbidity," BMJ News writes (Moszynski, 8/3).

5 Aug 2010

Nature News examines how scientists, farmers are working to meet the growing demand for artemisinin

"From bust to boom to bust again: artemisinin, the key ingredient of front-line antimalarial drugs, is entering the third chapter of its turbulent history," Nature News writes in an article that examines the challenges scientists and farmers are facing as they attempt to keep up with the growing demand for the compound just as a "$343-million initiative starts to battle malaria through hugely subsidized medicines."

5 Aug 2010

President Obama, Sec. of State discuss U.S. commitment to development, fighting disease in Africa with young African leaders

During a gathering of over 100 young African business and civil leaders at the White House on Tuesday, President Barack Obama "urged [them] to help spur economic development and fight corruption, disease and extremism on the continent," MSNBC's "First Read" blog reports.

5 Aug 2010

Elusys awarded second contract to develop Anthim for treatment of anthrax infection

Elusys Therapeutics, Inc., a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to $143 million if all options are exercised by the Government.

5 Aug 2010

TapImmune inks smallpox vaccine Research and Technology License Option Agreement with Mayo Clinic

TapImmune Inc. announced that it has signed a Research and Technology License Option Agreement with Mayo Clinic, Rochester, MN, for the development of a smallpox vaccine technology. Research will be conducted by Gregory Poland M.D., at Mayo Clinic, to evaluate novel peptide antigens together with TapImmune's proprietary TAP technology. TapImmune also has an exclusive Option to the smallpox vaccine technology after research studies have been completed under the terms of the agreement.

5 Aug 2010

Disease/Infection News

Bloomberg Businessweek explores growing trend in pharma to license, donate HIV drugs

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Boston Globe examines rise of polio in Tajikistan, other pockets of world

Multiple tattoos increase risk of contracting hepatitis C: Study

Equatorial Guinea, ECCAS partner to form network to fight H1N1, HIV

Recent releases in Global Health

Dermatologist discusses on common nail ailment prevention

Kaiser Family Foundation/CSIS forum reviews AIDS 2010, looks ahead to AIDS 2012

Risk of epidemic is high in Pakistan: Canadian Red Cross

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Research on human disease origins to predict, prevent next outbreak

SeraCare optimizes ACCURUN 341 Nucleic Acid Positive controls

Scientists to develop new antibiotics to tackle infection-causing bacteria

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Researchers map malaria parasite P vivax; Nearly 3B people at risk of infection in 2009

Nature News examines how scientists, farmers are working to meet the growing demand for artemisinin

President Obama, Sec. of State discuss U.S. commitment to development, fighting disease in Africa with young African leaders

Elusys awarded second contract to develop Anthim for treatment of anthrax infection

TapImmune inks smallpox vaccine Research and Technology License Option Agreement with Mayo Clinic

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News